After Cara Therapeutics announced that the Independent Data Monitoring Committee for its KALM-2 Phase 3 clinical trial of Korsuva Injection in hemodialysis patients with chronic kidney disease-associated pruritus recommended that the size of the trial will be increased by about 20% to 430 patients, Stifel analyst Annabel Samimy said she is still optimistic on the program. She suspects the multi-site, international nature of the study may have introduced more variability and noted that the company expects to complete the increase by the end of Q4, which would keep them on track for filing in the second half of 2020. The analyst, who also is still positive on the upcoming oral Korsuva readout in Q4, keeps a Buy rating and $33 price target on Cara shares.